T1	PROC 1 51	Estudio comparativo, cruzado, doble ciego, al azar
#1	AnnotatorNotes T1	C0150097; Cross-Over Studies; Research Activity + C0683941; comparative analysis; Research Activity + C0013072; Double-Blind Method; Research Activity + C0034656; Randomization; Research Activity
T2	CHEM 114 123	valsartán
#2	AnnotatorNotes T2	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T3	PROC 166 218	estudios de bioequivalencia o equivalencia comparada
T4	PROC 57 86	determinar la bioequivalencia
T5	CHEM 288 305	producto genérico
#3	AnnotatorNotes T5	C0085155; Generic Drugs; Pharmacologic Substance
T6	PROC 743 790	se evaluará y se comparará la biodisponibilidad
T7	CHEM 794 803	valsartán
#4	AnnotatorNotes T7	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T8	CHEM 808 831	agente antihipertensivo
#5	AnnotatorNotes T8	C0003364; Antihypertensive Agents; Pharmacologic Substance
T9	CHEM 832 896	inhibidor específico del receptor de angiotensina II subtipo AT1
#6	AnnotatorNotes T9	C1449680; Angiotensin II Type 1 Receptor Blockers; Pharmacologic Substance
T10	ANAT 905 924	membranas celulares
#7	AnnotatorNotes T10	C0007603; Plasma membrane; Cell Component
T11	ANAT 929 950	músculo liso vascular
#8	AnnotatorNotes T11	C4082861; Vascular smooth muscle cell; Cell
T12	PROC 963 989	Evaluar la bioequivalencia
T13	CHEM 997 1020	productos farmacéuticos
#9	AnnotatorNotes T13	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T14	CHEM 1046 1055	valsartán
#10	AnnotatorNotes T14	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T15	CHEM 1186 1195	valsartán
#11	AnnotatorNotes T15	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T16	PROC 1316 1376	estudio aleatorizado, cruzado, a doble ciego, de dosis única
T17	PROC 1490 1501	tratamiento
#12	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	CHEM 1539 1548	valsartán
#13	AnnotatorNotes T18	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T19	PROC 1612 1623	tratamiento
#14	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	ANAT 1645 1656	plasmáticas
#15	AnnotatorNotes T20	C0032105; Plasma; Body Substance
T21	PROC 1674 1681	HPLC/UV
#16	AnnotatorNotes T21	C0201764; High performance liquid chromatography, UV type; Laboratory Procedure
T22	CHEM 1730 1738	losartán
#17	AnnotatorNotes T22	C0126174; losartan; Organic Chemical · Pharmacologic Substance
T23	CHEM 1796 1805	valsartán
#18	AnnotatorNotes T23	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T24	CHEM 1945 1954	valsartán
#19	AnnotatorNotes T24	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T25	ANAT 2189 2200	plasmáticas
#20	AnnotatorNotes T25	C0032105; Plasma; Body Substance
T26	CHEM 2258 2267	valsartán
#21	AnnotatorNotes T26	C0216784; valsartan; Organic Chemical · Pharmacologic Substance
T27	PROC 2358 2368	protocolos
#22	AnnotatorNotes T27	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T28	CHEM 1026 1042	principio activo
#23	AnnotatorNotes T28	C1372955; Active ingredient; Chemical Viewed Functionally
T29	PROC 1091 1115	medidas farmacocinéticas
#24	AnnotatorNotes T29	C0201734; Pharmacokinetic study; Research Activity
T30	ANAT 1219 1228	sanguínea
#25	AnnotatorNotes T30	C0005767; Blood; Body Substance
T31	PROC 1244 1269	administrado por vía oral
#26	AnnotatorNotes T31	C0001563; Administration, Oral; Therapeutic or Preventive Procedure | C1273553; Oral administration of treatment; Therapeutic or Preventive Procedure
T32	PROC 2215 2229	administración
#27	AnnotatorNotes T32	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T33	Form 127 135	tabletas
#28	AnnotatorNotes T33	C0039225; Tablet Dosage Form; Functional Concept
T34	Form 138 146	cápsulas
#29	AnnotatorNotes T34	C4722245; Capsule Dose Form Category; Functional Concept
T37	PHYS 653 669	farmacocinéticos
#30	AnnotatorNotes T37	C0031327; Drug Kinetics; Physiologic Function
T38	PHYS 1099 1115	farmacocinéticas
#31	AnnotatorNotes T38	C0031327; Drug Kinetics; Physiologic Function
T40	PHYS 1207 1228	circulación sanguínea
#32	AnnotatorNotes T40	C0005775; Blood Circulation; Physiologic Function
T41	Route 1261 1269	vía oral
#33	AnnotatorNotes T41	C1527415; Oral Route of Drug administration; Functional Concept
T42	Dose 1365 1376	dosis única
T43	Age 1412 1430	entre 19 y 28 años
T44	Dose 1516 1535	una dosis de 320 mg
T46	Duration 1578 1584	8 días
T47	Form 1784 1792	tabletas
#34	AnnotatorNotes T47	C0039225; Tablet Dosage Form; Functional Concept
T48	PHYS 1846 1862	farmacocinéticas
#35	AnnotatorNotes T48	C0031327; Drug Kinetics; Physiologic Function
T50	Duration 1919 1922	2 h
T51	Form 1933 1941	cápsulas
#36	AnnotatorNotes T51	C4722245; Capsule Dose Form Category; Functional Concept
T52	PHYS 1995 2011	farmacocinéticas
#37	AnnotatorNotes T52	C0031327; Drug Kinetics; Physiologic Function
T54	Duration 2068 2073	2.5 h
T56	Dose 2269 2274	80 mg
T57	Form 2275 2283	tabletas
#38	AnnotatorNotes T57	C0039225; Tablet Dosage Form; Functional Concept
T58	Dose 2286 2291	80 mg
T59	Form 2292 2300	cápsulas
#39	AnnotatorNotes T59	C4722245; Capsule Dose Form Category; Functional Concept
T35	LIVB 1275 1286	voluntarios
#40	AnnotatorNotes T35	C0020155; Human Volunteers; Population Group
T36	LIVB 1383 1400	voluntarios sanos
#41	AnnotatorNotes T36	C1708335; Healthy Volunteers; Population Group
T39	CHEM 253 272	producto en estudio
#42	AnnotatorNotes T39	C0013230; Investigational New Drugs; Pharmacologic Substance
T45	PROC 2316 2334	diseño del estudio
#43	AnnotatorNotes T45	C0035171; Research Design; Research Activity
T49	Neg_cue 2115 2117	no
T53	CONC 2128 2139	diferencias
A1	Assertion T53 Negated
R1	Negation Arg1:T49 Arg2:T53	
#44	AnnotatorNotes T53	C1705241; Delta (difference); Quantitative Concept
R2	Has_Drug_Form Arg1:T2 Arg2:T33	
R3	Has_Drug_Form Arg1:T2 Arg2:T34	
T55	CONC 322 339	biodisponibilidad
#45	AnnotatorNotes T55	C0005508; Biological Availability; Quantitative Concept
T60	CONC 71 86	bioequivalencia
#46	AnnotatorNotes T60	C0039789; Therapeutic Equivalency; Qualitative Concept
T61	CONC 178 193	bioequivalencia
#47	AnnotatorNotes T61	C0039789; Therapeutic Equivalency; Qualitative Concept
T62	CONC 539 554	bioequivalencia
#48	AnnotatorNotes T62	C0039789; Therapeutic Equivalency; Qualitative Concept
T63	CONC 974 989	bioequivalencia
#49	AnnotatorNotes T63	C0039789; Therapeutic Equivalency; Qualitative Concept
T64	CONC 2404 2419	bioequivalencia
#50	AnnotatorNotes T64	C0039789; Therapeutic Equivalency; Qualitative Concept
T65	CONC 446 461	bioequivalentes
#51	AnnotatorNotes T65	C0039789; Therapeutic Equivalency; Qualitative Concept
T66	CONC 673 691	área bajo la curva
#52	AnnotatorNotes T66	C0376690; Area Under Curve; Quantitative Concept
T67	CONC 693 696	ABC
#53	AnnotatorNotes T67	C0376690; Area Under Curve; Quantitative Concept
T68	CONC 722 726	Cmáx
#54	AnnotatorNotes T68	C2347813; Cmax; Quantitative Concept
T69	CONC 700 720	concentración máxima
#55	AnnotatorNotes T69	C2347813; Cmax; Quantitative Concept
T70	CONC 2036 2040	Cmáx
#56	AnnotatorNotes T70	C2347813; Cmax; Quantitative Concept
T71	CONC 1887 1891	Cmáx
#57	AnnotatorNotes T71	C2347813; Cmax; Quantitative Concept
T72	CONC 642 669	parámetros farmacocinéticos
T73	CONC 773 790	biodisponibilidad
#58	AnnotatorNotes T73	C0005508; Biological Availability; Quantitative Concept
R4	Has_Drug_Form Arg1:T26 Arg2:T59	
R5	Has_Dose_or_Strength Arg1:T26 Arg2:T56	
R6	Has_Dose_or_Strength Arg1:T26 Arg2:T58	
R7	Has_Drug_Form Arg1:T26 Arg2:T57	
R8	Has_Drug_Form Arg1:T24 Arg2:T51	
R9	Has_Drug_Form Arg1:T23 Arg2:T47	
T74	CONC 1835 1862	parámetros farmacocinéticas
T75	CONC 1984 2011	parámetros farmacocinéticas
R11	Used_for Arg1:T15 Arg2:T31	
R12	Has_Route_or_Mode Arg1:T15 Arg2:T41	
R13	Experiences Arg1:T35 Arg2:T15	
R14	Experiences Arg1:T35 Arg2:T40	
R16	Experiences Arg1:T35 Arg2:T13	
R17	Experiences Arg1:T35 Arg2:T28	
R18	Experiences Arg1:T35 Arg2:T14	
R19	Experiences Arg1:T35 Arg2:T29	
R20	Experiences Arg1:T35 Arg2:T38	
R21	Has_Age Arg1:T36 Arg2:T43	
R22	Used_for Arg1:T18 Arg2:T17	
T76	Quantifier_or_Qualifier 1457 1469	dos períodos
R23	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T76	
R24	Has_Dose_or_Strength Arg1:T18 Arg2:T44	
T77	CONC 1557 1574	período de lavado
#59	AnnotatorNotes T77	C1710661; Washout Period; Temporal Concept
R25	Has_Duration_or_Interval Arg1:T77 Arg2:T46	
T78	Quantifier_or_Qualifier 1594 1601	primero
R26	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T78	
T79	Quantifier_or_Qualifier 1604 1611	segundo
R27	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T79	
R28	After Arg1:T19 Arg2:T77	
R29	Before Arg1:T19 Arg2:T77	
R30	After Arg1:T17 Arg2:T77	
R31	Before Arg1:T17 Arg2:T77	
R32	Location_of Arg1:T20 Arg2:T21	
T80	CONC 1864 1867	ABC
#60	AnnotatorNotes T80	C0376690; Area Under Curve; Quantitative Concept
T81	CONC 2013 2016	ABC
#61	AnnotatorNotes T81	C0376690; Area Under Curve; Quantitative Concept
T82	CONC 2060 2064	Tmáx
#62	AnnotatorNotes T82	C2348796; Tmax; Quantitative Concept
T83	CONC 1911 1915	Tmáx
#63	AnnotatorNotes T83	C2348796; Tmax; Quantitative Concept
R33	Overlap Arg1:T83 Arg2:T50	
R42	Overlap Arg1:T82 Arg2:T54	
R43	After Arg1:T53 Arg2:T32	
R44	Used_for Arg1:T26 Arg2:T32	
T84	CONC 2173 2200	concentraciones plasmáticas
#64	AnnotatorNotes T84	C0683150; plasma concentration; Quantitative Concept
T85	CONC 1629 1656	concentraciones plasmáticas
#65	AnnotatorNotes T85	C0683150; plasma concentration; Quantitative Concept
T86	Quantifier_or_Qualifier 2140 2154	significativas
A2	Assertion T86 Negated
#66	AnnotatorNotes T86	C0750502; Significant; Idea or Concept
R45	Has_Quantifier_or_Qualifier Arg1:T53 Arg2:T86	
R46	Negation Arg1:T49 Arg2:T86	
#67	AnnotatorNotes T78	C0205435; First (number); Quantitative Concept
R10	Overlap Arg1:T71 Arg2:T50	
R15	Overlap Arg1:T80 Arg2:T50	
R34	Overlap Arg1:T74 Arg2:T50	
R35	Overlap Arg1:T81 Arg2:T54	
R36	Overlap Arg1:T70 Arg2:T54	
R37	Overlap Arg1:T75 Arg2:T54	
#68	AnnotatorNotes T79	C0205436; second (number); Quantitative Concept
#69	AnnotatorNotes T72	C0031328; Pharmacokinetic aspects; Functional Concept
#70	AnnotatorNotes T74	C0031328; Pharmacokinetic aspects; Functional Concept
#71	AnnotatorNotes T75	C0031328; Pharmacokinetic aspects; Functional Concept
#72	AnnotatorNotes T6	C1706947; Bioavailability Study; Research Activity
A3	Assertion T65 Hypothetical
A4	Experiencer T35 Patient
A5	Experiencer T36 Patient
